PROGNOSTIC VALUE IN PREDICTING OVERALL SURVIVAL OF 2 MUCINOUS MARKERS - CA-15-3 AND CA-125 IN BREAST-CANCER PATIENTS AT FIRST RELAPSE OF DISEASE
PROGNOSTIC VALUE IN PREDICTING OVERALL SURVIVAL OF 2 MUCINOUS MARKERS - CA-15-3 AND CA-125 IN BREAST-CANCER PATIENTS AT FIRST RELAPSE OF DISEASE
复制标题
DOI：
10.1016/0959-8049(94)00356-a
复制
发表时间：
1994-01-01
影响因子：
8.4
通讯作者：
DOGLIOTTI, L
中科院分区：
文献类型：
--
作者：
BERRUTI, A;TAMPELLINI, M;DOGLIOTTI, L
循环肿瘤标志物在提供预后信息方面的作用几乎没有研究。我们在115例首次复发的乳腺癌患者中评估了两种粘液标记物CA 15-3和CA 125的预后意义。在诊断为晚期疾病时，发现64例患者骨受累，57例肺受累，21例皮肤淋巴结受累，20例肝受累，5例脑受累。招募患者并在同一机构接受常规化疗或内分泌治疗。随访时间范围为3至54+个月（中位数35）。在开始任何内分泌和/或化疗之前，在疾病首次复发时抽取血清样本。CA 15-3 30 U/ml的患者（中位50+ vs 26个月，P
The role of circulating tumour markers in providing prognostic information has been scarcely studied. We evaluated the prognostic significance of two mucinous markers: CA 15-3 and CA 125 in 115 breast cancer patients at first recurrence of disease. At diagnosis of advanced disease bone involvement was found in 64 patients, lung in 57, skin lymph nodes in 21, liver in 20, and brain in 5. Patients were recruited and treated in the same institution with conventional chemo- or endocrine therapy. The follow-up ranged from 3 to 54+ months (median 35). Serum samples were drawn at first recurrence of disease before the start of any endocrine and/or chemotherapy. Patients with CA 15-3 30 U/ml (median 50+ versus 26 months, P